Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate Probuphine is a long-acting formulation of buprenorphine designed for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan’s proprietary drug delivery system ProNeura, which is capable of delivering sustained, consistent levels of medication for six months or longer. For more information, visit the company’s website at www.titanpharm.com.